COLLEGIUM PHARMACEUTICAL, INC (COLL)
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 3Completed
Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)
Oxycodone DETERx, Placebo
Chronic Low Back Pain
NCT01685684Enrollment740StartAug 2012Primary CompletionJun 2014CompletionJul 2014
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | Oxycodone DETERx, Placebo | NCT01685684 |